According to well-established criteria, a molecular analysis of exon 2 (codons 12 and 13) is routinely performed in formalin-fixed, paraffin-embedded (FFPE) tissue and the identification of a wild-type (WT) KRAS tumor may lead to a more tumor-specific and less toxic treatment for the patient. The gene discussed is KRAS; the disease is neoplasm.